FindTrial
Sign In

Effects of Baduanjin on anxiety, depression and quality of life in patients with primary glaucoma: a randomized clinical trial

Effects of Baduanjin on anxiety, depression and quality of life in patients with primary glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084185
Enrollment
Unknown
Registered
2024-05-11
Start date
2024-05-15
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary glaucoma

Interventions

Test group:On the basis of routine nursing measures and outpatient follow-up, Baduanjin exercise was done five times a week for 30 minutes each time for 8 weeks.
Control group:Routine nursing measures and outpatient follow-up lasted for 8 weeks

Sponsors

The Third People's Hospital of Chengdu
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG) in Chinese Glaucoma guidelines (2020). (2) The vital signs are stable and have normal communication and understanding ability. (3) There is no limb motor dysfunction. (4) Knowing and agreeing to complete this study.

Exclusion criteria

Exclusion criteria: (1) Patients with glaucoma other than POAG and PACG. (2) Having severe mental disorders or take psychotropic drugs. (3) Cognitive impairment. (4) Limb motor dysfunction. (5) Severe somatic diseases, unable to complete this study.

Design outcomes

Primary

MeasureTime frame
Anxiety and depression;—

Secondary

MeasureTime frame
Quality of life;Sleep quality;—

Countries

China

Contacts

Public ContactZengzhen

The Third People's Hospital of Chengdu

cherry5295@qq.com+86 137 0820 6907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026